1.Clinical application of human serum kallikrein 6 for the diagnosis and monitor of epithelial ovarian cancer
Xufang QIAN ; Xiaojun YANG ; Xiangxiang BAO ; Yunqin CHEN ; Feiyun ZHENG ; Cixia SHUAI ; Wenhui ZHANG
Journal of Chinese Physician 2009;11(6):734-737
Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pithelial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma, 20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CAi25 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women (P < 0.05). KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease (P < 0. 05). On the contrary, KLK6 showed no significant correlation with pathological types (P >0. 05). After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma (P < 0. 05). Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85.0% respectively, followed by the sensitivity to be 50. 0% and 88. 9% for the diagnosis of stage Ⅰ-Ⅱand Ⅲ-Ⅳ disease. Conclusion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.
2.The changes of macular choroidal thickness in patients with mild to moderate Alzheimer's disease
Jing BAO ; Zhigang LYU ; Xiangxiang ZHANG ; Danni YE
Chinese Journal of Ocular Fundus Diseases 2019;35(3):231-234
Objective To obverse the changes ofmacular choroidal thickness (CT) in patients with mild to moderate Alzheimer's disease (AD).Methods This was a case-control study.Twenty-one patients with mild to moderate AD confirmed by Neurology Department of Jinhua Central Hospital from November 2016 to June 2018 and 21 age-matched control subjects were concluded in the study.There was no significant difference in age (t=0.128),intraocular pressure (t=0.440) and axial length (t=1.202) between the two groups (P>0.05).There was significant difference in mini-mental state examination score (t=8.608,P<0.05).CT was measured by OCT with enhanced depth imaging technique in the subfoveal choroid,at 0.5 mm and 1.0 mm from the center of the fovea nasal (NCT0.5,1.0mm),temporal (TCT0.5,1.0mm),superior (SCT0.5,1.0mm),and inferior (ICT0.5,1.0mm).Independent-samples t test was used to compare the results obtained from these two groups.Results SFCT (t=2.431),NCT0.5,1.0 mm (t=3.341,2.640),TCT0.5,1.0 mm (t=3.340,2.899),SCT0.5.1.0 mm (t=3.576,3.751) and ICT0.5 (t=2.897,2.903) were significantly thinner in AD eyes than those in control eyes.Conclusion Compared with healthy subjects,patients with mild to moderate AD showed a significant reduction in CT.
3.Targeting the chromatin structural changes of antitumor immunity
Li NIAN-NIAN ; Lun DENG-XING ; Gong NINGNING ; Meng GANG ; Du XIN-YING ; Wang HE ; Bao XIANGXIANG ; Li XIN-YANG ; Song JI-WU ; Hu KEWEI ; Li LALA ; Li SI-YING ; Liu WENBO ; Zhu WANPING ; Zhang YUNLONG ; Li JIKAI ; Yao TING ; Mou LEMING ; Han XIAOQING ; Hao FURONG ; Hu YONGCHENG ; Liu LIN ; Zhu HONGGUANG ; Wu YUYUN ; Liu BIN
Journal of Pharmaceutical Analysis 2024;14(4):460-482
Epigenomic imbalance drives abnormal transcriptional processes,promoting the onset and progression of cancer.Although defective gene regulation generally affects carcinogenesis and tumor suppression networks,tumor immunogenicity and immune cells involved in antitumor responses may also be affected by epigenomic changes,which may have significant implications for the development and application of epigenetic therapy,cancer immunotherapy,and their combinations.Herein,we focus on the impact of epigenetic regulation on tumor immune cell function and the role of key abnormal epigenetic processes,DNA methylation,histone post-translational modification,and chromatin structure in tumor immunogenicity,and introduce these epigenetic research methods.We emphasize the value of small-molecule inhibitors of epigenetic modulators in enhancing antitumor immune responses and discuss the challenges of developing treatment plans that combine epigenetic therapy and immuno-therapy through the complex interaction between cancer epigenetics and cancer immunology.